BTEC.L vs. DOCT.L
BTEC.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) and DOCT.L (L&G Healthcare Breakthrough UCITS ETF) are both Health & Biotech Equities funds - BTEC.L tracks the NASDAQ Biotechnology NET Index while DOCT.L tracks the MSCI World/Health Care NR USD. Both are passively managed. Over the past 5 years, BTEC.L returned 5.94%/yr vs -3.22%/yr for DOCT.L. A 0.79 correlation means they provide meaningful diversification when combined. BTEC.L charges 0.35%/yr vs 0.49%/yr for DOCT.L.
Performance
BTEC.L vs. DOCT.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BTEC.L achieves a 15.64% return, which is significantly higher than DOCT.L's 6.56% return.
BTEC.L
- 1D
- 0.42%
- 1M
- 8.47%
- 6M
- 14.00%
- YTD
- 15.64%
- 1Y
- 47.62%
- 3Y*
- 17.00%
- 5Y*
- 5.94%
- 10Y*
- —
DOCT.L
- 1D
- -1.55%
- 1M
- 7.35%
- 6M
- 1.34%
- YTD
- 6.56%
- 1Y
- 36.62%
- 3Y*
- 7.90%
- 5Y*
- -3.22%
- 10Y*
- —
BTEC.L vs. DOCT.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 15.64% | 32.96% | -2.04% | 6.22% | -11.92% | -0.49% | 27.40% | 10.88% |
DOCT.L L&G Healthcare Breakthrough UCITS ETF | 6.56% | 24.90% | 1.96% | -1.16% | -33.86% | 0.19% | 66.94% | 10.00% |
Correlation
The correlation between BTEC.L and DOCT.L is 0.70, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.70 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.73 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.77 |
Correlation (All Time) Calculated using the full available price history since Jun 26, 2019 | 0.79 |
The correlation between BTEC.L and DOCT.L has been stable across timeframes, ranging from 0.70 to 0.79 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEC.L vs. DOCT.L — Risk / Return Rank
BTEC.L
DOCT.L
BTEC.L vs. DOCT.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and L&G Healthcare Breakthrough UCITS ETF (DOCT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BTEC.L | DOCT.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.63 | ||
| Sortino ratioReturn per unit of downside risk | +0.72 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.29 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.97 | 2.14 | +3.83 |
| Martin ratioReturn relative to average drawdown | 18.32 | 5.02 | +13.30 |
Loading charts...
Drawdowns
BTEC.L vs. DOCT.L - Drawdown Comparison
The maximum BTEC.L drawdown since its inception was -38.42%, smaller than the maximum DOCT.L drawdown of -57.54%. Use the drawdown chart below to compare losses from any high point for BTEC.L and DOCT.L.
Loading charts...
Drawdown Indicators
| BTEC.L | DOCT.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.42% | -57.54% | +19.12% |
Max Drawdown (1Y)Largest decline over 1 year | -7.94% | -17.02% | +9.08% |
Max Drawdown (3Y)Largest decline over 3 years | -26.74% | -28.75% | +2.01% |
Max Drawdown (5Y)Largest decline over 5 years | -38.42% | -55.80% | +17.38% |
Current DrawdownCurrent decline from peak | -3.51% | -25.42% | +21.91% |
Average DrawdownAverage peak-to-trough decline | -13.22% | -28.91% | +15.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.59% | 7.28% | -4.69% |
Volatility
BTEC.L vs. DOCT.L - Volatility Comparison
The current volatility for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) is 5.44%, while L&G Healthcare Breakthrough UCITS ETF (DOCT.L) has a volatility of 6.86%. This indicates that BTEC.L experiences smaller price fluctuations and is considered to be less risky than DOCT.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEC.L | DOCT.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.44% | 6.86% | -1.42% |
Volatility (6M)Calculated over the trailing 6-month period | 15.67% | 16.71% | -1.04% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.42% | 21.54% | -1.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.38% | 24.12% | -2.74% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.37% | 24.67% | -2.30% |
BTEC.L vs. DOCT.L - Expense Ratio Comparison
BTEC.L has a 0.35% expense ratio, which is lower than DOCT.L's 0.49% expense ratio.
Dividends
BTEC.L vs. DOCT.L - Dividend Comparison
Neither BTEC.L nor DOCT.L has paid dividends to shareholders.
Frequently Asked Questions
BTEC.L and DOCT.L have a correlation of 0.70, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEC.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEC.L is cheaper with a 0.35% expense ratio, compared with 0.49% for DOCT.L.
BTEC.L tracks NASDAQ Biotechnology NET Index, while DOCT.L tracks MSCI World/Health Care NR USD. They also come from different issuers: iShares and Legal & General. Their fees differ too: 0.35% for BTEC.L and 0.49% for DOCT.L.
Find the right allocation for BTEC.L and DOCT.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer